The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan
Status:
Withdrawn
Trial end date:
2022-10-13
Target enrollment:
Participant gender:
Summary
This is a multi-center, non-randomized, open-label, parallel group, multiple-dose study to
assess the pharmacokinetic, safety, and tolerability of balovaptan in male and female
subjects with moderate hepatic impairment compared to healthy subjects with normal hepatic
function matched by age (±10 years), sex, and body mass index (BMI; ±20%).